Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Ann Oncol
    August 2025
  1. RAY-COQUARD I, Cropet C, Harter P, Pujade-Lauraine E, et al
    Reply to Letter to the Editor "Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer" by Arenhardt and Nogueira-Rodrigues.
    Ann Oncol. 2025 Aug 4:S0923-7534(25)00832-4. doi: 10.1016/j.annonc.2025.
    >> Share

    July 2025
  2. ARENHARDT MP, Nogueira-Rodrigues A
    Re: Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer.
    Ann Oncol. 2025 Jul 7:S0923-7534(25)00831-2. doi: 10.1016/j.annonc.2025.
    >> Share

    May 2025
  3. HARDY-BESSARD AC, Pujade-Lauraine E, Moore RG, Montestruc F, et al
    Dostarlimab and niraparib in primary advanced ovarian cancer.
    Ann Oncol. 2025 May 30:S0923-7534(25)00201-7. doi: 10.1016/j.annonc.2025.
    >> Share

    March 2025
  4. CHAMBERS LM, Eskander RN, O'Malley DM
    Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era.
    Ann Oncol. 2025;36:244-246.
    >> Share

    November 2024
  5. SECORD AA, Lewin SN, Murphy CG, Cecere SC, et al
    The Efficacy and Safety of Mirvetuximab Soravtansine in FRalpha-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.
    Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.
    >> Share

  6. HARTER P, Marth C, Mouret-Reynier MA, Cropet C, et al
    Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
    Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.
    >> Share

    September 2024
  7. MONK BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, et al
    Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Ann Oncol. 2024 Sep 14:S0923-7534(24)03762-1. doi: 10.1016/j.annonc.2024.08.2241
    >> Share

    January 2024
  8. LEDERMANN JA, Matias-Guiu X, Amant F, Concin N, et al
    ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
    Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.
    >> Share

    December 2023
  9. MCNEISH IA, Monk BJ
    Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma.
    Ann Oncol. 2023;34:1074-1076.
    >> Share

    October 2023
  10. SESSA C, Paluch-Shimon S
    Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian canc
    Ann Oncol. 2023 Oct 26:S0923-7534(23)04325-9. doi: 10.1016/j.annonc.2023.
    >> Share

  11. TJALMA WAA
    There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes.
    Ann Oncol. 2023 Oct 20:S0923-7534(23)04324-7. doi: 10.1016/j.annonc.2023.
    >> Share

  12. PUJADE-LAURAINE E, Selle F, Scambia G, Asselain B, et al
    Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
    Ann Oncol. 2023 Oct 3:S0923-7534(23)04007-3. doi: 10.1016/j.annonc.2023.09.3110.
    >> Share

    August 2023
  13. GONZALEZ-MARTIN A, Harter P, Leary A, Lorusso D, et al
    Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Ann Oncol. 2023 Aug 10:S0923-7534(23)00797-4. doi: 10.1016/j.annonc.2023.
    >> Share

    May 2023
  14. RAY-COQUARD I, Leary A, Pignata S, Cropet C, et al
    Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
    Ann Oncol. 2023 May 19:S0923-7534(23)00686-5. doi: 10.1016/j.annonc.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016